These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 36585453)
1. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Gulhati P; Schalck A; Jiang S; Shang X; Wu CJ; Hou P; Ruiz SH; Soto LS; Parra E; Ying H; Han J; Dey P; Li J; Deng P; Sei E; Maeda DY; Zebala JA; Spring DJ; Kim M; Wang H; Maitra A; Moore D; Clise-Dwyer K; Wang YA; Navin NE; DePinho RA Nat Cancer; 2023 Jan; 4(1):62-80. PubMed ID: 36585453 [TBL] [Abstract][Full Text] [Related]
2. Targeting both tumour-associated CXCR2 Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437 [TBL] [Abstract][Full Text] [Related]
3. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Blair AB; Kim VM; Muth ST; Saung MT; Lokker N; Blouw B; Armstrong TD; Jaffee EM; Tsujikawa T; Coussens LM; He J; Burkhart RA; Wolfgang CL; Zheng L Clin Cancer Res; 2019 Sep; 25(17):5351-5363. PubMed ID: 31186314 [TBL] [Abstract][Full Text] [Related]
4. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647 [TBL] [Abstract][Full Text] [Related]
6. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Li P; Rozich N; Wang J; Wang J; Xu Y; Herbst B; Yu R; Muth S; Niu N; Li K; Funes V; Gai J; Osipov A; Edil BH; Wolfgang CL; Lei M; Liang T; Zheng L Cancer Lett; 2022 Jul; 539():215722. PubMed ID: 35533951 [TBL] [Abstract][Full Text] [Related]
7. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma. Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673 [TBL] [Abstract][Full Text] [Related]
8. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073 [TBL] [Abstract][Full Text] [Related]
9. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870 [TBL] [Abstract][Full Text] [Related]
17. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S Front Immunol; 2021; 12():648917. PubMed ID: 33777046 [No Abstract] [Full Text] [Related]
18. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091 [TBL] [Abstract][Full Text] [Related]
19. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951 [TBL] [Abstract][Full Text] [Related]
20. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer. Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]